

Carmen Baldazzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8998611/publications.pdf>

Version: 2024-02-01

79
papers

937
citations

686830

13
h-index

454577

30
g-index

79
all docs

79
docs citations

79
times ranked

1633
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients. <i>Leukemia Research</i> , 2021, 101, 106497.	0.4	3
2	Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations. <i>Leukemia</i> , 2021, 35, 2813-2826.	3.3	15
3	Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway. <i>Blood Cancer Journal</i> , 2021, 11, 7.	2.8	3
4	MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2020, 105, 47-55.	1.1	4
5	Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting. <i>Blood</i> , 2020, 136, 14-15.	0.6	0
6	Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1951.	1.7	17
7	Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. <i>Cancer</i> , 2019, 125, 712-725.	2.0	49
8	Abstract 2140: Upâ€•a new adult Philadelphia negative acute lymphoblastic leukemia subgroup: Novel molecular markers. , 2019, , .		0
9	The Use of Venetoclax for Acute Myeloid Leukemia in a Real-Life Setting: A Multicenter National Experience. <i>Blood</i> , 2019, 134, 5098-5098.	0.6	0
10	AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA). <i>Blood</i> , 2019, 134, 2617-2617.	0.6	0
11	Abstract 3100: Blinatumomab is safe and effective in relapsed and MRD positive B-ALL CD19+ patients: The bologna compassionate program experience. , 2019, , .		0
12	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. <i>Leukemia</i> , 2018, 32, 1609-1620.	3.3	80
13	Tyrosine Kinase Inhibitors (TKI) in Relapsed/Refractory (RR) Patients with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Confer Better Survival than Chemotherapy, Due to a Better Safety Profile. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S200.	0.2	0
14	Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival. <i>Stem Cell Research and Therapy</i> , 2018, 9, 271.	2.4	63
15	Age, Disease Status before Blinatumomab, MRD Negativity Obtainment, and Bridge to Transplant Influence Outcome in Patients with B-ALL: A Single Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S181-S182.	0.2	0
16	Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 99.	6.9	35
17	Abstract 2951: Gene expression profiling identifies new adult "triple-negative" acute lymphoblastic leukemia (ALL) subgroups. , 2018, , .		0
18	Abstract 656: Distinct pattern of alterations in TP53 mutated/deleted and wild-type high risk acute myeloid leukemia (AML) patients: Identification of new "targetable" genes/pathways. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
19	A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups. <i>Blood</i> , 2018, 132, 5284-5284.	0.6	0
20	Mitoxantrone, Etoposide and Cytarabine (MEC) Can Induce Deep Complete Remission and Is an Effective Bridge Therapy to Allogeneic Transplantation (SCT) in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients. <i>Blood</i> , 2018, 132, 4036-4036.	0.6	2
21	Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics. <i>Blood</i> , 2018, 132, 2748-2748.	0.6	0
22	Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells. <i>Haematologica</i> , 2017, 102, 1204-1214.	1.7	8
23	Chromothripsis in acute myeloid leukemia: Biological features and impact on survival. <i>Leukemia</i> , 2017, , .	3.3	3
24	Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7038-7038.	0.8	2
25	Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. <i>Oncotarget</i> , 2017, 8, 29906-29913.	0.8	22
26	Copy number variants signature in two patients with relapsed acute promyelocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23207-e23207.	0.8	0
27	Microarray analysis to identify novel copy number alterations in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11622-11622.	0.8	0
28	Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11611-11611.	0.8	0
29	Abstract 1766: Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients. , 2017, , .		0
30	Abstract 3472: Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels. , 2017, , .		0
31	<scp>FGFR</scp>1 and <scp>KAT6A</scp> rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features. <i>American Journal of Hematology</i> , 2016, 91, E14-6.	2.0	4
32	Complex chromosomal rearrangements leading to <scp><i>MECOM</i></scp> overexpression are recurrent in myeloid malignancies with various 3q abnormalities. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 375-388.	1.5	5
33	Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50. <i>Blood</i> , 2016, 128, 1702-1702.	0.6	1
34	Pharmacological interaction and side effects in oncohaematology: a retrospective observational study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18235-e18235.	0.8	0
35	Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7044-7044.	0.8	0
36	Abstract 90: A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia. <i>Cancer Research</i> , 2016, 76, 90-90.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Abstract 113: Novel fusion transcripts identified by RNAseq cooperate with somatic mutations in the pathogenesis of acute myeloid leukemia. , 2016, , .		0
38	Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis. Blood, 2016, 128, 1677-1677.	0.6	0
39	Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML). Blood, 2016, 128, 1679-1679.	0.6	1
40	4q12 translocations with <i>GSL1</i> expression identify a <i>CD7+</i> acute myeloid leukaemia subset. British Journal of Haematology, 2015, 171, 141-145.	1.2	6
41	RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia. Blood, 2015, 126, 3627-3627.	0.6	2
42	Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. Oncotarget, 2015, 6, 31284-31294.	0.8	18
43	Abstract B03: Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome.. , 2015, , .		0
44	Abstract 4906: TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome. , 2015, , .		0
45	Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients. Blood, 2015, 126, 3198-3198.	0.6	0
46	Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2015, 126, 2513-2513.	0.6	0
47	A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene. Blood, 2015, 126, 1356-1356.	0.6	0
48	A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium. Blood, 2015, 126, 3840-3840.	0.6	0
49	Upregulation of Indoleamine 2,3-Dioxygenase Enzymes in Leukemic Mesenchymal Stromal Cells (MSCs) Can Influence MSC/Acute Myeloid Leukemia Cell Cross Talk. Blood, 2015, 126, 1191-1191.	0.6	0
50	Abstract 746: PKC412 (Midostaurin) is safe and highly effective in systemic mastocytosis patients: Follow up of a single-center Italian compassionate use. , 2014, , .		1
51	Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients. Blood, 2014, 124, 1040-1040.	0.6	2
52	Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome. Blood, 2014, 124, 484-484.	0.6	3
53	PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis: Follow up of a single-center Italian compassionate use.. Journal of Clinical Oncology, 2014, 32, 7113-7113.	0.8	0
54	Abstract 570:Tp53mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
55	Abstract CT312: Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience. , 2014, , .		0
56	SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients. Blood, 2014, 124, 1030-1030.	0.6	0
57	Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing. Blood, 2014, 124, 1028-1028.	0.6	1
58	Next-Generation Sequencing Analysis Revealed That BCL11B Chromosomal Translocation Cooperates with Point Mutations in the Pathogenesis of Acute Myeloid Leukemia. Blood, 2014, 124, 2352-2352.	0.6	0
59	Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis. Blood, 2013, 122, 2622-2622.	0.6	11
60	Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q). Blood, 2013, 122, 5227-5227.	0.6	0
61	Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harboring T315I Mutation: The Bologna Experience. Blood, 2013, 122, 3911-3911.	0.6	0
62	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood, 2012, 120, 761-767.	0.6	110
63	A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia. Hematology Reports, 2012, 4, e27.	0.3	1
64	Abstract 906:Gas1andKif27genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients. , 2012, , .		2
65	PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience. Blood, 2012, 120, 1749-1749.	0.6	0
66	Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood, 2011, 117, 6793-6800.	0.6	98
67	PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients. Blood, 2011, 118, 1429-1429.	0.6	3
68	Gas1 and Kif27 Genes Are Strongly up-Regulated Biomarkers of Hedgehog Inhibition (PF-04449913) on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients. Blood, 2011, 118, 1535-1535.	0.6	3
69	Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). Blood, 2011, 118, 2756-2756.	0.6	7
70	C22orf2 Gene (22q13.1) Translocation Downstream of Bcr Breakpoint (22q11) to the Derivative 9 Chromosome Is Associated with Reduced Expression of Its Protein, the Beta-Catenin Antagonist Chibby, in Chronic Myeloid Leukemia Progenitors. Blood, 2011, 118, 1676-1676.	0.6	0
71	Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. Cancer Genetics and Cytogenetics, 2010, 199, 76-80.	1.0	28
72	B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. Leukemia Research, 2010, 34, e282-e285.	0.4	37

#	ARTICLE	IF	CITATIONS
73	Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. <i>Leukemia Research</i> , 2009, 33, e218-e220.	0.4	9
74	Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1 ⁺ positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). <i>Blood</i> , 2009, 114, 2159-2167.	0.6	201
75	Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. <i>Leukemia and Lymphoma</i> , 2009, 50, 114-118.	0.6	9
76	Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. <i>Blood</i> , 2009, 114, 4939-4943.	0.6	62
77	Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL).. <i>Blood</i> , 2009, 114, 167-167.	0.6	1
78	Acute promyelocytic leukemia with amplification of PML-RAR1± rearrangement: Clinical implications. <i>Leukemia Research</i> , 2008, 32, 1941-1943.	0.4	3
79	Deletions of the Derivative Chromosome 9 Do Not Influence Response to Imatinib of Early Chronic Phase Chronic Myeloid Leukemia Patients (A GIMEMA Working Party Analysis).. <i>Blood</i> , 2006, 108, 2112-2112.	0.6	1